Updates Center

• 
  COMPANY ANNOUNCEMENT

  AtaGenix Laboratories Co., Ltd. issues a formal statement addressing the unauthorized use of its name by Wuhan Biolab-reagent, which forged documents and official seals, constituting illegal activity and unfair competition. The company clarifies that no business agreements exist with Wuhan Biolab-reagent, condemns their actions, and reserves the right to pursue legal action under Chinese intellectual property and criminal laws. AtaGenix advises partners to verify document authenticity to avoid legal and financial risks, reaffirming its commitment to honest operation and industry fairness.
• 
  International Life Sciences Leaders Visit AtaGenix: Advancing Antibody R&D with Velocity and Rigor

  On October 14, 2025, AtaGenix in Wuhan, China, welcomed global life sciences representatives to explore its 6-month antibody R&D platform, marking a biotech collaboration milestone.
• 
  AtaGenix at AACR 2026 | Custom Antibody Development & abinScience Reagents

  AtaGenix showcased custom antibody development services and the abinScience catalog of 35,000+ research reagents at AACR 2026 Booth #1761 in San Diego. Explore antibodies, recombinant proteins, ELISA kits, in vivo antibodies, and anti-idiotype antibodies for oncology and drug development research.
• 
  VINS Visits AtaGenix Wuhan HQ for Biopharma Partnership

  On June 25, 2025, VINS Bioproducts visited AtaGenix’s Wuhan headquarters to expand collaboration on vaccine raw materials, antibody R&D, and CRO services—advancing public health and innovation.
• 
  AtaGenix Excels at Thailand LAB International 2025: Pioneering Antibody Discovery & Protein Expression

  AtaGenix Laboratories Co., Ltd. participated in Thailand LAB International 2025 in Bangkok from September 3-5, showcasing advanced antibody discovery and protein expression technologies at booth 2S21. Through technical exhibits, seminars, and business discussions, AtaGenix established global partnerships, reinforcing its leadership in the Asia-Pacific biotechnology market.
• 
  AtaGenix September 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  The AtaGenix September 2025 Literature Collection highlights the company’s pivotal role in supporting groundbreaking life science research. Featuring studies published in high-impact journals like Journal of Nanobiotechnology and Cell Reports, this collection showcases advancements in lipid nanoparticle-based mRNA vaccines, gastric cancer drug resistance mechanisms, LayV virus antigenicity, jujube centromere evolution, and tomato plant vigor regulation. AtaGenix’s technical services, including custom antibodies and hybridoma screening tools, were instrumental in these discoveries, reinforcing its commitment to driving innovation in life sciences.
• 
  AtaGenix October 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  In October 2025, AtaGenix delivered critical antibody solutions for seven groundbreaking studies published in Cell (IF 42.5), Nature Plants (IF 13.6), and other leading journals. Research spanned insect endosymbiont tubenets, Bacteroidota T6SS co-secretion, Brassica pancentromere dynamics, lysosomal damage in Duchenne muscular dystrophy, and more. Custom anti-Lpp, CENH3, SiFBA4, and anti-R99me2a antibodies enabled immunogold labeling, ChIP-seq, protein quantification, and translational regulation studies—overcoming key experimental hurdles. Over 500 SCI papers have now cited AtaGenix’s one-stop protein and antibody development platform. The ongoing literature reward program continues to incentivize citations.
• 
  A Wild Collection: The Most Unusual Species AtaGenix Has Worked With

  Since 2011, AtaGenix has delivered one-stop custom solutions for over 100 species worldwide. This article presents verified cases from Nature Communications, Nature Genetics, and other top journals, systematically demonstrating expertise in antibody development, protein production, and expression systems across plants (rice, chili), mammals (mouse, chicken), insects (diamondback moth), aquatic organisms (grass carp, shrimp), fungi (Mycobacterium tuberculosis), and parasites (Cryptosporidium), embodying truly “boundless” research customization.
• 
  AtaGenix November 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  In November 2025, AtaGenix proudly supported four high-impact publications spanning oncology, infectious diseases, and agricultural biotechnology. Featured research includes a novel ZUP1-targeted strategy to overcome olaparib resistance in triple-negative breast cancer, an engineered Mycoplasma pneumoniae strain that degrades dual-species biofilms, a low-cost Meta-SPR biomolecular detection platform, and the repurposing of clotrimazole as an eco-friendly fungicide against rice blast. Through recombinant protein purification, custom antibody development, and affinity validation services, AtaGenix continues to accelerate cutting-edge life science discoveries worldwide.
• 
  AtaGenix December 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  AtaGenix's December 2025 literature collection showcases two high-impact publications supported by its advanced protein and antibody technologies. The studies, published in Advanced Science (IF 14.1) and Molecular Therapy (IF 12), address critical challenges in neurogenic bladder fibrosis—identifying Itga8 as a key therapeutic target—and on-target/off-tumor toxicities in low-affinity Nectin-4-specific CAR-T therapy for solid tumors. These achievements highlight AtaGenix's vital role in enabling cutting-edge life science research and clinical translation.